Two medicines, side by side
Quetiapine vs lurasidone
Quetiapine and lurasidone are both labeled for depression, bipolar disorder and schizophrenia. Drugs@FDA records approvals of quetiapine since 1997 and of lurasidone since 2010. Pharmacies paid $0.127 per quetiapine fumarate 300 mg tablet and $0.142 per lurasidone HCl 20 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. How each works, in its label's words: Quetiapine, “The mechanism of action of quetiapine in the listed indications is unclear.”; Lurasidone, “The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear.”
Check it at the source: the quetiapine FDA label on DailyMed (effective April 10, 2026); the lurasidone FDA label on DailyMed (effective January 31, 2025).
Highlights of the quetiapine record
Quetiapine (Seroquel) · label of April 10, 2026
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1) ]. SEROQUEL is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ].
Used for
From the label: indicationsSEROQUEL is an atypical antipsychotic indicated for the treatment of: • Schizophrenia ( 1.1 ) • Bipolar I disorder manic episodes (1.2) • Bipolar disorder, depressive episodes (1.2) 1.1 Schizophrenia SEROQUEL is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13-17 years). […]
On the market
- Earliest approval on file
- September 26, 1997
- Generic labelers
- 48 labelers
- Pharmacy cost
- $0.127 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 10
Highlights of the lurasidone record
Lurasidone (Latuda) · label of January 31, 2025
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis ( 5.1 ).
Used for
From the label: indicationsLATUDA is indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies ( 14.1 )]. Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )]. […]
On the market
- Earliest approval on file
- October 28, 2010
- Generic labelers
- 28 labelers
- Pharmacy cost
- $0.142 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 2
Source: FDA drug labels via openFDA (Quetiapine label of April 10, 2026, Lurasidone label of January 31, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do quetiapine and lurasidone differ on the record?
How each works, in its label's words: Quetiapine, “The mechanism of action of quetiapine in the listed indications is unclear.”; Lurasidone, “The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear.”
Both are in FDA's class atypical antipsychotics.
Both labels carry a boxed warning; the records quote them.
Generics: quetiapine since 2012; lurasidone since 2019 (Drugs@FDA).
| Quetiapine | Lurasidone | |
|---|---|---|
| Labeled for | Schizophrenia, Bipolar disorder, Depression | Schizophrenia, Bipolar disorder, Depression |
| Pharmacologic class | Atypical Antipsychotic | Atypical Antipsychotic |
| How it works (label) | The mechanism of action of quetiapine in the listed indications is unclear. However, the efficacy of quetiapine in these indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism. | The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. |
| Half-life (label) | Elimination of quetiapine is mainly via hepatic metabolism with a mean terminal half-life of about 6 hours within the proposed clinical dose range. | n/a |
| Earliest approval on file (Drugs@FDA) | September 26, 1997 | October 28, 2010 |
| First generic approved | March 27, 2012 | January 3, 2019 |
| Generic labelers (NDC) | 48 labelers | 28 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.127 per tablet (Quetiapine fumarate 300 mg tablet) | $0.142 per tablet (Lurasidone HCl 20 mg tablet) |
| 12-month price change | -9% | -28% |
| Boxed warning | Yes | Yes |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 10 | 2 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 191,480 | 20,803 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
Do their labels mention each other?
Lurasidone label, warnings and precautionsChange in weight from baseline for olanzapine was +4.15 kg and for quetiapine extended-release was +2.09 kg in Studies 3 and 5 [see Clinical Studies ( 14.1 )], respectively.
Source: FDA drug labels via openFDA
What next?
- Alternatives to quetiapine
- every medicine labeled for the same conditions